{
    "clinical_study": {
        "@rank": "109454", 
        "acronym": "ITT-5", 
        "arm_group": [
            {
                "arm_group_label": "Acyline; T Gel; placebo dutasteride, placebo ketoconazole", 
                "arm_group_type": "Experimental", 
                "description": "All men will receive Acyline 300 ug/kg subcutaneous (SQ) injections every 2-weeks + Testosterone 1% Gel 5g daily and then randomly assigned.\nGroup 1: placebo oral ketoconazole + placebo oral dutasteride for 4 months"
            }, 
            {
                "arm_group_label": "Acyline; T gel; Ketoconazole; placebo", 
                "arm_group_type": "Experimental", 
                "description": "All men will receive Acyline 300 ug/kg SQ injections every 2-weeks + Testosterone 1% Gel 5g daily and then randomly assigned.\nGroup 2: oral ketoconazole 400 mg + placebo oral dutasteride for 4 months"
            }, 
            {
                "arm_group_label": "Acyline; Tgel; Ketoconazole; Dutasteride", 
                "arm_group_type": "Experimental", 
                "description": "All men will receive Acyline 300 ug/kg SQ injections every 2-weeks + Testosterone 1% Gel 5g daily and then randomly assigned.\nGroup 3: Ketoconazole 400mg orally daily + Dutasteride 2.5 mg orally on day 1, followed by 0.5mg daily for 4 months"
            }, 
            {
                "arm_group_label": "Acyline; Tgel; HCG", 
                "arm_group_type": "Experimental", 
                "description": "All men will receive Acyline 300 ug/kg SQ injections every 2-weeks + Testosterone 1% Gel 5g daily and then randomly assigned.\nGroup 4: Human Chorionic gonadotropin (HCG) 60 IU injection every other day for 4 months."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this investigational drug study is to determine how much male hormone,\n      testosterone, is needed to maintain sperm production in the testis."
        }, 
        "brief_title": "ITT-5 Mechanisms of Spermatogenesis", 
        "completion_date": {
            "#text": "December 2018", 
            "@type": "Anticipated"
        }, 
        "condition": "Gonadotropin Deficiency", 
        "condition_browse": {
            "mesh_term": "Hypogonadism"
        }, 
        "detailed_description": {
            "textblock": "This is a nine-month research study examining the effects on androgen treatment on sperm\n      production in healthy men.  There are three phase to the study, a 2-month screening phase,\n      4-month treatment and 3-month follow-up. In this study, the investigators aim to define a\n      quantitative relationship between intra-testicular testosterone (IT-T) and spermatogenesis\n      in man.  Hormone levels will be measured in a small amount of testicular fluid at the\n      beginning and end of treatment and sperm concentration will be measured."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Males age 18-55\n\n          -  In general good health based on normal screening evaluation\n\n          -  Normal serum testosterone, lutenizing hormone (LH) and follicle stimulating hormone\n             (FSH)\n\n          -  Prostate Specific Antigen (PSA)  < 3.0\n\n          -  Agrees not to donate blood or participate in another research study during the study\n\n          -  Informed consent\n\n          -  Must be willing to use a reliable form of contraception during the study\n\n        Exclusion Criteria:\n\n          -  Participation in a long-term male contraceptive study within the past three months\n\n          -  History of testosterone or anabolic steroid abuse in the past\n\n          -  History of or current skin disorder that will interfere with testosterone gel\n\n          -  Poor general health or significantly abnormal screening blood results\n\n          -  History of or current testicular or prostate disease\n\n          -  History of a bleeding disorder or need for anticoagulation\n\n          -  History of untreated sleep apnea and/or major psychiatric problems\n\n          -  BMI > 32\n\n          -  History of or current liver disease\n\n          -  Chronic pain syndrome\n\n          -  Current use of terfenidine, astemizole, cisapride, budesonide, felodipine,\n             fluticasone,  lovastatin, midazolam, sildenafil, or vardenafil\n\n          -  Use of glucocorticoids or underlying adrenal insufficiency\n\n          -  Active drug or alcohol abuse within the past year"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 21, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02147964", 
            "org_study_id": "47124-A"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Acyline; T Gel; placebo dutasteride, placebo ketoconazole", 
                    "Acyline; T gel; Ketoconazole; placebo", 
                    "Acyline; Tgel; Ketoconazole; Dutasteride", 
                    "Acyline; Tgel; HCG"
                ], 
                "description": "Testosterone 1% gel 5g daily for 4 months [all subjects]", 
                "intervention_name": "Testosterone 1% Gel", 
                "intervention_type": "Drug", 
                "other_name": [
                    "T gel", 
                    "Testosterone gel", 
                    "AndroGel"
                ]
            }, 
            {
                "arm_group_label": [
                    "Acyline; T Gel; placebo dutasteride, placebo ketoconazole", 
                    "Acyline; T gel; Ketoconazole; placebo", 
                    "Acyline; Tgel; Ketoconazole; Dutasteride", 
                    "Acyline; Tgel; HCG"
                ], 
                "description": "Acyline 300 ug/kg SQ injections every 2-weeks for 4 months [all subjects]", 
                "intervention_name": "Acyline", 
                "intervention_type": "Drug", 
                "other_name": "acyline"
            }, 
            {
                "arm_group_label": "Acyline; Tgel; Ketoconazole; Dutasteride", 
                "description": "Dutasteride 2.5 mg (day 1) followed by 0.5 mg daily for 4 months", 
                "intervention_name": "Dutasteride", 
                "intervention_type": "Drug", 
                "other_name": "Avodart"
            }, 
            {
                "arm_group_label": [
                    "Acyline; T gel; Ketoconazole; placebo", 
                    "Acyline; Tgel; Ketoconazole; Dutasteride"
                ], 
                "description": "ketoconazole 400 mg PO daily for 4 months", 
                "intervention_name": "Ketoconazole", 
                "intervention_type": "Drug", 
                "other_name": "Ketoconazole"
            }, 
            {
                "arm_group_label": "Acyline; Tgel; HCG", 
                "description": "HCG 60 IU injection Subcutaneously, every other day for 4 months", 
                "intervention_name": "HCG", 
                "intervention_type": "Drug", 
                "other_name": "Human chorionic gonadotropin (HCG)"
            }, 
            {
                "arm_group_label": [
                    "Acyline; T Gel; placebo dutasteride, placebo ketoconazole", 
                    "Acyline; T gel; Ketoconazole; placebo"
                ], 
                "description": "placebo oral dutasteride PO daily for 4 months", 
                "intervention_name": "placebo dutasteride", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Acyline; T Gel; placebo dutasteride, placebo ketoconazole", 
                "description": "placebo ketoconazole daily for 4 months", 
                "intervention_name": "placebo ketoconazole", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Testosterone", 
                "Testosterone enanthate", 
                "Testosterone undecanoate", 
                "Testosterone 17 beta-cypionate", 
                "Methyltestosterone", 
                "Chorionic Gonadotropin", 
                "Ketoconazole", 
                "Dutasteride"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "intratesticular androgens", 
            "testosterone", 
            "dutasteride", 
            "gonadotropin suppression", 
            "male contraception", 
            "spermatogenesis"
        ], 
        "lastchanged_date": "May 27, 2014", 
        "link": {
            "description": "Dedicated to basic and clinical research focused primarily on the male reproductive system", 
            "url": "http://depts.washington.edu/popctr/"
        }, 
        "location": {
            "contact": {
                "email": "inielsen@uw.edu", 
                "last_name": "Iris Nielsen", 
                "phone": "206-221-5473"
            }, 
            "contact_backup": {
                "email": "klwinter@uw.edu", 
                "last_name": "Kathy Winter", 
                "phone": "206-616-0484"
            }, 
            "facility": {
                "address": {
                    "city": "Seattle", 
                    "country": "United States", 
                    "state": "Washington", 
                    "zip": "98195"
                }, 
                "name": "University of Washington Medical Center (Health Sciences)"
            }, 
            "investigator": [
                {
                    "last_name": "Mara Roth, MD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "John Amory, MD, MPH", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Stephanie Page, MD, PhD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Bradley Anawalt, MD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "4", 
        "official_title": "Mechanisms of Hormonal Control of Spermatogenesis in Man", 
        "overall_contact": {
            "email": "inielsen@uw.edu", 
            "last_name": "Iris Nielsen", 
            "phone": "206-221-5473"
        }, 
        "overall_contact_backup": {
            "email": "klwinter@uw.edu", 
            "last_name": "Kathy Winter", 
            "phone": "206-616-0484"
        }, 
        "overall_official": [
            {
                "affiliation": "University of Washington", 
                "last_name": "Mara Roth, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "University of Washington", 
                "last_name": "William J Bremner, MD, PhD", 
                "role": "Study Director"
            }
        ], 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Difference in sperm concentration at week 16 between 4 treatment groups", 
            "measure": "Sperm concentration", 
            "safety_issue": "No", 
            "time_frame": "16 weeks"
        }, 
        "reference": [
            {
                "PMID": "1977002", 
                "citation": "[No authors listed] Contraceptive efficacy of testosterone-induced azoospermia in normal men. World Health Organization Task Force on methods for the regulation of male fertility. Lancet. 1990 Oct 20;336(8721):955-9."
            }, 
            {
                "PMID": "8774299", 
                "citation": "Wu FC, Farley TM, Peregoudov A, Waites GM. Effects of testosterone enanthate in normal men: experience from a multicenter contraceptive efficacy study. World Health Organization Task Force on Methods for the Regulation of Male Fertility. Fertil Steril. 1996 Mar;65(3):626-36."
            }, 
            {
                "PMID": "10386821", 
                "citation": "Anawalt BD, Bebb RA, Bremner WJ, Matsumoto AM. A lower dosage levonorgestrel and testosterone combination effectively suppresses spermatogenesis and circulating gonadotropin levels with fewer metabolic effects than higher dosage combinations. J Androl. 1999 May-Jun;20(3):407-14."
            }, 
            {
                "PMID": "2498065", 
                "citation": "Zirkin BR, Santulli R, Awoniyi CA, Ewing LL. Maintenance of advanced spermatogenic cells in the adult rat testis: quantitative relationship to testosterone concentration within the testis. Endocrinology. 1989 Jun;124(6):3043-9."
            }, 
            {
                "PMID": "19779211", 
                "citation": "Roth MY, Lin K, Amory JK, Matsumoto AM, Anawalt BD, Snyder CN, Kalhorn TF, Bremner WJ, Page ST. Serum LH correlates highly with intratesticular steroid levels in normal men. J Androl. 2010 Mar-Apr;31(2):138-45. Epub 2009 Sep 24."
            }, 
            {
                "PMID": "20484472", 
                "citation": "Roth MY, Page ST, Lin K, Anawalt BD, Matsumoto AM, Snyder CN, Marck BT, Bremner WJ, Amory JK. Dose-dependent increase in intratesticular testosterone by very low-dose human chorionic gonadotropin in normal men with experimental gonadotropin deficiency. J Clin Endocrinol Metab. 2010 Aug;95(8):3806-13. doi: 10.1210/jc.2010-0360. Epub 2010 May 19."
            }, 
            {
                "PMID": "2966691", 
                "citation": "Trachtenberg J, Zadra J. Steroid synthesis inhibition by ketoconazole: sites of action. Clin Invest Med. 1988 Feb;11(1):1-5."
            }, 
            {
                "PMID": "2499150", 
                "citation": "Nashan D, Knuth UA, Weidinger G, Nieschlag E. The antimycotic drug terbinafine in contrast to ketoconazole lacks acute effects on the pituitary-testicular function of healthy men: a placebo-controlled double-blind trial. Acta Endocrinol (Copenh). 1989 May;120(5):677-81."
            }, 
            {
                "PMID": "6093722", 
                "citation": "Pont A, Graybill JR, Craven PC, Galgiani JN, Dismukes WE, Reitz RE, Stevens DA. High-dose ketoconazole therapy and adrenal and testicular function in humans. Arch Intern Med. 1984 Nov;144(11):2150-3."
            }, 
            {
                "PMID": "6151171", 
                "citation": "Van Tyle JH. Ketoconazole. Mechanism of action, spectrum of activity, pharmacokinetics, drug interactions, adverse reactions and therapeutic use. Pharmacotherapy. 1984 Nov-Dec;4(6):343-73. Review."
            }, 
            {
                "PMID": "23348398", 
                "citation": "Roth MY, Nya-Ngatchou JJ, Lin K, Page ST, Anawalt BD, Matsumoto AM, Marck BT, Bremner WJ, Amory JK. Androgen synthesis in the gonadotropin-suppressed human testes can be markedly suppressed by ketoconazole. J Clin Endocrinol Metab. 2013 Mar;98(3):1198-206. doi: 10.1210/jc.2012-3527. Epub 2013 Jan 24."
            }, 
            {
                "PMID": "15713727", 
                "citation": "Coviello AD, Matsumoto AM, Bremner WJ, Herbst KL, Amory JK, Anawalt BD, Sutton PR, Wright WW, Brown TR, Yan X, Zirkin BR, Jarow JP. Low-dose human chorionic gonadotropin maintains intratesticular testosterone in normal men with testosterone-induced gonadotropin suppression. J Clin Endocrinol Metab. 2005 May;90(5):2595-602. Epub 2005 Feb 15."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02147964"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of Washington", 
            "investigator_full_name": "Mara Roth", 
            "investigator_title": "Assistant Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "It steroid concentration at week 16 between the 4 treatment groups", 
            "measure": "IT steroid concentration", 
            "safety_issue": "No", 
            "time_frame": "16 weeks"
        }, 
        "source": "University of Washington", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of Washington", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}